Description
Accession
GP100
Source
DNA sequence encoding the Human (HLA-A*02:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the GP100 (PMEL) peptide YLEPGPVTA .This complex includes a C terminal polyHis AVI tag and was expressed in HEK cells,
Molecular weight
Recombinant HLA-A/GP100 has a calculated mass of approximately 50kDa. Due to glycosylation migrates as an approximately 60 kDa protein under reducing conditions in SDS-PAGE.
Purity
purity was determined to be >95% by nonreducing PAGE and HPLC (see below methods)
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation
Recombinant HLA-A*02:01 GP100 was lyophilized from 0.2 µm filtered PBS solution pH7.4
Reconstitution
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Storage
The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Usage
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Methods
HLA-A*02:01 GP100 complex HPLC
- The purity of GP100 (HLA-A*02:01)complex was greater than 95% as determined by SEC-HPLC.
HLA-A*02:01 GP100 peptide complex PAGE
- 1ug loaded Tris-Bis PAGE under reducing condition. The purity is greater than 95%.
HLA-A*02:01 GP100 complex peptide complex ELISA
- Dose response curve for Anti-HLA-A*02:01 GP100 Antibody
